ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
31 Luglio 2024 - 11:30AM
ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”)
(Nasdaq: ALXO), an immuno-oncology company developing therapies
that block the CD47 immune checkpoint pathway, announced that the
Company will host an investor conference call and webcast today at
4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06
clinical trial evaluating evorpacept for the treatment of advanced
HER2-positive gastric cancer.
To access the live conference call, please dial (800) 715-9871
(U.S./Canada) or +44.800.260.6466 (internationally), Conference ID
9637001. To access the live and archived webcast of the conference
call, please visit the News & Events section (see
“Events") of the Company’s website
at www.alxoncology.com, where a slide presentation will be
referenced during the event.
Company Contact: Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology, cdoherty@alxoncology.com, (650) 466-7125
Investor Contact: Malini Chatterjee, Ph.D, Blueprint Life Science Group, (917) 330-4269
Media Contact: Audra Friis, Sam Brown, Inc., audrafriis@sambrown.com, (917) 519-9577
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Lug 2024 a Ago 2024
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Ago 2023 a Ago 2024